EPISODE · Nov 7, 2022 · 29 MIN
Helen Ayles and Musonda Simwinge on the PopART trial
from The Lancet HIV in conversation with · host The Lancet HIV
Helen Ayles (London School of Hygiene and Tropical Medicine) and Musonda Simwinga (Zambart) join Peter Hayward to discuss PopART trial (HPTN 071) papers published in the November issue of The Lancet HIV. Read the PopART trial papers: Viral suppression and self-reported ART adherence after 3 years of universal testing and treatment in the HPTN 071 (PopART) community Impact of universal testing and treatment on sexual risk behaviour and herpes simplex virus type 2 Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
Embed this episode
What this episode covers
Helen Ayles (London School of Hygiene and Tropical Medicine) and Musonda Simwinga (Zambart) join Peter Hayward to discuss PopART trial (HPTN 071) papers published in the November issue of The Lancet HIV. Read the PopART trial papers: Viral suppression and self-reported ART adherence after 3 years of universal testing and treatment in the HPTN 071 (PopART) community Impact of universal testing and treatment on sexual risk behaviour and herpes simplex virus type 2 Projected outcomes of unive...
Ready to play
Helen Ayles and Musonda Simwinge on the PopART trial
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.